## 1

#### Interpretation – the Aff may not specify a medicine to waive IP protections for

#### Medicines is a generic bare plural

**Leslie and Lerner 16** [Sarah-Jane Leslie (Ph.D., Princeton, 2007) is the dean of the Graduate School and Class of 1943 Professor of Philosophy. She has previously served as the vice dean for faculty development in the Office of the Dean of the Faculty, director of the Program in Linguistics, and founding director of the Program in Cognitive Science at Princeton University. She is also affiliated faculty in the Department of Psychology, the University Center for Human Values, the Program in Gender and Sexuality Studies, and the Kahneman-Treisman Center for Behavioral Science and Public Policy], and Adam Lerner, Ph.D, Postgraduate Research Associate in the Department of Philosophy at Princeton University, 4-24-2016, accessed 9-4-2021, "Generic Generalizations (Stanford Encyclopedia of Philosophy)," <https://plato.stanford.edu/entries/generics/>] HWIC

There are some tests that are helpful in distinguishing these two readings. For example, the existential interpretation is upward entailing, meaning that the statement will always remain true if we replace the subject term with a more inclusive term. Consider our examples above. In ([1b](https://plato.stanford.edu/entries/generics/#ex1b)), we can replace “tiger” with “animal” salva veritate, but in ([1a](https://plato.stanford.edu/entries/generics/#ex1a)) we cannot. If “tigers are on the lawn” is true, then “animals are on the lawn” must be true. However, “tigers are striped” is true, yet “animals are striped” is false. ([1a](https://plato.stanford.edu/entries/generics/#ex1a)) does not entail that animals are striped, but ([1b](https://plato.stanford.edu/entries/generics/#ex1b)) entails that animals are on the front lawn (Lawler 1973; Laca 1990; Krifka et al. 1995).

Another test concerns whether we can insert an adverb of quantification with minimal change of meaning (Krifka et al. 1995). For example, inserting “usually” in the sentences in ([1a](https://plato.stanford.edu/entries/generics/#ex1a)) (e.g., “tigers are usually striped”) produces only a small change in meaning, while inserting “usually” in ([1b](https://plato.stanford.edu/entries/generics/#ex1b)) dramatically alters the meaning of the sentence (e.g., “tigers are usually on the front lawn”). (For generics such as “mosquitoes carry malaria”, the adverb “sometimes” is perhaps better used than “usually” to mark off the generic reading.)

#### It applies to this topic – “Member nations ought to reduce IP for covid – therefore, member nations ought to eliminate IP reduce IP for all” is illogical

#### 1] Limits: There’s inf medicines they could specify, coupled with various types of countries. Kills neg burdens – it’s impossible for me to research every possible combination of the 195 countries and medicines.

#### 2] TVA Solves – just read your aff as an advantage to a whole rez aff. We aren’t stopping them from reading new FWs, mechanisms, or advantages. PICs don’t solve – it’s ridiculous to say that neg potential abuse justifies the aff making it impossible for me to win

#### Drop the debater on T: Drop the arg is severance since you jump shift from your advocacy which perpetuates abuse since it allows you to restart the round. Competing interps: 1. Reasonability causes a race to the bottom where we read increasingly unfair practices that minimally fit the brightline 2. Collapses- you use offense-defense to determine reasonability being good which concedes the authority of competing interps 3. Reasonability makes no sense on T- you’re either topical or you’re not, you can’t be 87% topical. No RVIs: 1. Illogical- being topical doesn’t mean you should win, it’s just a burden. 2. Chilling effect- debaters will be scared to read theory for fear of losing to a prepped out counter interp, proliferating abuse. 3. RVI’s kill norming: I can’t concede the counter-interp mid-round if I realize it’s wrong so you force me to argue for bad norms

## 2

#### The standard is maximizing expected well being. prefer it:

#### 1] Actor specificity: A] Governments must aggregate since every policy benefits some and harms others, which also means side constraints freeze action. B] States lack wills or intentions since policies are collective actions. Actor-specificity comes first since different agents have different ethical standings. Takes out util calc indicts since they’re empirically denied and link turns them because the alt would be *no* action.

#### 2] Util is a lexical pre-requisite to any other framework:

#### A] Threats to bodily security and life preclude the ability for moral actors to effectively utilize and act upon other moral theories since they are in a constant state of crisis that inhibit the ideal moral conditions which other theories presuppose – so, util comes first and my offense outweighs theirs under their own framework.

#### B] The only way that we know an action is good or bad is through its results. A violation of a constraint might be bad because it results in treating someone as a means. Talking about how we can only know intent does nothing for you: consequentialists concede this, and speculate about end states based on the aims of the actions.

#### 3] Weighability – only consequentialism explains degrees of wrongness—if I break a promise to meet up for lunch, that is not as bad as breaking a promise to take a dying person to the hospital. Only the consequences of breaking the promise explain why the second one is much worse than the first.

#### Extinction comes first under any moral framework:

#### ---A] It precludes the possibility of any kind of moral value – we can’t confer value onto anything if we’re not alive.

#### ---B] Contestation on the framework debate proves ethical uncertainty – uncertainty means we prioritize preventing extinction because that preserves our ability to find moral value in the future, regardless of what framework seems more correct now.

#### 1] Moral uncertainty means we should prevent extinction

Bostrom 12 [Nick Bostrom. Faculty of Philosophy & Oxford Martin School University of Oxford. “Existential Risk Prevention as Global Priority.” Global Policy (2012)]

These reflections on moral uncertainty suggest an alternative, complementary way of looking at existential risk; they also suggest a new way of thinking about the ideal of sustainability. Let me elaborate.¶ Our present understanding of axiology might well be confused. We may not now know — at least not in concrete detail — what outcomes would count as a big win for humanity; we might not even yet be able to imagine the best ends of our journey. If we are indeed profoundly uncertain about our ultimate aims, then we should recognize that there is a great option value in preserving — and ideally improving — our ability to recognize value and to steer the future accordingly. Ensuring that there will be a future version of humanity with great powers and a propensity to use them wisely is plausibly the best way available to us to increase the probability that the future will contain a lot of value. To do this, we must prevent any existential catastrophe.

## 3

#### Counterplan Text – the United States ought to

#### anonymously invest $25 billion into 25 production lines dedicated solely to COVID-19 vaccines to boost global vaccine production managed by the Biomedical Advanced Research and Development Authority.

#### anonymously pre-order and distribute 8 billion doses of COVID vaccines using an equitable distribution framework prioritizing developing countries in the Global South.

#### The CP solves the entirety of the case and does it faster.

Stankiewicz 21 Mike Stankiewicz 5-6-2021"Opinion: For just $25 billion, the U.S. could jump-start a project to quickly vaccinate the entire world against COVID" <https://www.marketwatch.com/story/for-just-25-billion-the-u-s-could-jump-start-a-project-to-quickly-vaccinate-the-entire-world-against-covid-11614898552> (a press officer in Public Citizen's communication's department, where he focuses on legislative policy and health-orientated advocacy)//

Despite wealthy countries such as the U.S. ramping up COVID-19 vaccination efforts, **it** still **may** **take years to vaccinate the world**, especially poorer countries, and the economic and humanitarian impacts could be devastating. But **an injection of** **just $25 billion** **into global vaccine production efforts by the U.S.** government **could save millions of lives** and help prevent economic disaster. The most up-to-date numbers paint incredibly different futures between wealthy and low-income countries. At the current rate of vaccination, analysts predict that developing countries, including almost all of Southeast Asia, may not reach meaningful vaccine coverage until 2023. Comparatively, President Joe Biden has promised that the U.S. will have enough vaccine doses to inoculate every adult within the next three months. Increased fatalities And as wealthy countries such as the U.S. are starting to see lower death, transmission and hospitalization rates, low-income countries are experiencing increased hardship and fatalities. Countries such as Hungry are being forced to tighten restrictions as infection rates increase, and deaths in Africa have spiked by 40% in the past month, according to the World Health Organization (WHO). No country can be left behind in this global pandemic, and the U.S. is in a unique position to make sure every country gets the ample amount of vaccines they need. **Public Citizen research has found that just a $25 billion investment in COVID-19 vaccine production by the U.S. government would produce enough vaccine for developing countries, potentially shaving years from the global pandemic**. Public Citizen estimates that **8 billion doses of** National Institutes of Health-**Moderna MRNA**, +1.98% vaccine can be **produced** **for** just over **$3 per dose**. To bolster production and supply the necessary 8 billion doses, it would take **$1.9 billion to fund** the necessary **25 production lines**. Another **$19 billion** would pay **for materials and labor**, and **$3 billion** would **compensate** **Moderna** **for making technology available to manufacturers** in other countries. An additional $500 million would cover costs to staff and run **a rapid-response federal program that provides technical assistance and facilitates technology transfer to manufacturers and works with the WHO’s technology hub.** In total, vaccinating the world would cost less than 1.4% the total of Biden’s $1.9 trillion COVID relief plan. But such a program also needs to be properly managed to be successful. To help facilitate these efforts, the Biden administration should also **designate** the government’s Biomedical Advanced Research and Development Authority (**BARDA**) **to lead** the world-wide **vaccine manufacturing effort**. BARDA has the **necessary experience to coordinate** **an initiative of this scale** with the WHO, building on its partnership to build pandemic flu manufacturing capacity in developing countries after the bird-flu scare of 2006. Widespread vaccines would help U.S. economy These efforts would dramatically increase access to vaccines in developing countries and speed up global vaccination by years, saving countless lives. But allowing the current vaccine supply crisis to continue is not just inhumane, it is also not in our own economic interest to do so.

## 4

#### Climate Patents and Innovation high now and solving Warming but COVID waiver sets a dangerous precedent for appropriations - the mere threat is sufficient is enough to kill investment.

Brand 5-26, Melissa. “Trips Ip Waiver Could Establish Dangerous Precedent for Climate Change and Other Biotech Sectors.” IPWatchdog.com | Patents & Patent Law, 26 May 2021, www.ipwatchdog.com/2021/05/26/trips-ip-waiver-establish-dangerous-precedent-climate-change-biotech-sectors/id=133964/. //sid

The biotech industry is making remarkable advancestowards climate change solutions, and it is precisely for this reason that it can expect to be in the crosshairs of potential IP waiver discussions. President Biden is correct to refer to climate change as an existential crisis. Yet it does not take too much effort to connect the dots between President Biden’s focus on climate change and his Administration’s recent commitment to waive global IP rights for Covid vaccines (TRIPS IP Waiver). “This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures.” If an IP waiver is purportedly necessary to solve the COVID-19 global health crisis (and of course [we dispute this notion](https://www.ipwatchdog.com/2021/04/19/waiving-ip-rights-during-times-of-covid-a-false-good-idea/id=132399/)), can we really feel confident that this or some future Administration will not apply the same logic to the climate crisis? And, without the confidence in the underlying IP for such solutions, what does this mean for U.S. innovation and economic growth? United States Trade Representative (USTR) [Katherine Tai](https://www.ipwatchdog.com/2021/05/05/tai-says-united-states-will-back-india-southafrica-proposal-waive-ip-rights-trips/id=133224/) was subject to questioning along this very line during a recent Senate Finance Committee hearing. And while Ambassador Tai did not affirmatively state that an IP waiver would be in the future for climate change technology, she surely did not assuage the concerns of interested parties. The United States has historically supported robust IP protection. This support is one reason the United States is the center of biotechnology innovation and leading the fight against COVID-19. However, a brief review of the domestic legislation arguably most relevant to this discussion shows just how far the international campaign against IP rights has eroded our normative position. The Clean Air Act, for example, contains a provision allowingCovid-19 has supercharged innovation in the status quo

Ramalingam & Prabhu 20 [Ben Ramalingam- Overseas Development Institute, United Kingdom. Jaideep Prabhu University of Cambridge, United Kingdom. “Innovation, development and COVID-19: Challenges, opportunities and ways forward.” OECD. 1 December 2020. Link: https://www.oecd.org/coronavirus/policy-responses/innovation-development-and-covid-19-challenges-opportunities-and-ways-forward-0c976158/] JV

Coronavirus (COVID-19) innovation: what is happening? A global perspective At the same time as causing a huge impact on health and livelihoods around the world, COVID-19 has a created fertile breeding ground for novel solutions and approaches (OECD Observatory of Public Sector Innovation, n.d.[2]). The most comprehensive survey of global research and development (R&D) funding commitments for COVID-19, undertaken by the US-based Policy Cures programme, shows that investment in health-related innovation has been unprecedented (Policy Cures, 2020[3]). The scale of innovation resources mobilised globally is remarkable: USD 9 billion in seven months. By comparison, the total global funding disbursed for Ebola R&D between 2014 and 2018 was USD1.9 billion. The nature of the innovation processes that have been deployed is also notable. In the six months since the outbreak began, the US Food and Drug Administration (FDA) has approved almost 100 COVID-19 tests, in contrast to the three months the FDA took to approve the first Ebola test during the 2014 West Africa outbreak. The first COVID-19 vaccine entered into human trials within a record-breaking 69 days of identifying the causative agent of the outbreak1 – a remarkable achievement, considering that it took 25 months for the first vaccine to reach the human trial stage during the previous global coronavirus outbreak (SARS in 2002–04).

The risks associated with creating new drugs means that patents are key to biopharmaceutical innovation

Cockburn & Long 15 [Iain Cockburn, Richard C. Shipley Professor of Management. Genia Long, senior advisor and part of analysis group. “The importance of patents to innovation: updates cross-industry comparison with biopharmaceuticals.” Taylor & Francis online, Volume 25, Issue 7, 2015. Published online: 30 April 2015. Link: https://www.tandfonline.com/doi/full/10.1517/13543776.2015.1040762] JV

Due to distinctive economic characteristics, patents and regulatory exclusivity have long been considered essential to prescription drug development. These characteristics include the costly, lengthy, and risky nature of innovative research and development (R&D) and the much lower investment required for generic drugs. Because of this disparity, without patent protection and regulatory exclusivity, particularly in the USA, innovators would be unlikely to make the substantial investments required to bring new drugs to market. Whereas drug development is global, patent law and regulation are country-specific. In the USA, regulatory exclusivity operates in parallel with patents, defining when generics or biosimilars may not submit abbreviated applications and/or enter the market. Generic imitation may require several million dollars, whereas the cost to bring a single FDA-approved drug to market (including the cost of failed attempts) has been estimated at $1.4 billion in out-of-pocket costs and $2.6 billion including the cost of capital [1,2]. New drug R&D requires more than a decade, including pre-clinical testing, clinical trials, and US regulatory approval [1,2]. In comparison, clinical testing is not required for generics; manufacturers need only demonstrate bioequivalence to an already-approved drug. Risk is also high; the vast majority of candidates are eliminated, most before clinical testing. For those that begin clinical testing, the probability of proceeding to approval averages only 12% [2,3]. Therefore, R&D must be funded by a few successful, on-market medicines [4]. Generally, in the USA, once patent protection and any 180-day generic exclusivity end, multiple generics launch, and generic share increases rapidly. For all new molecular entities experiencing first generic entry in 2011–12, the average brand’s unit share of molecule sales declined to 16% 12 months after generic entry, versus 44% in 1999–00 [5]. In 2013, generics represented 86% of all US prescriptions [6]. In addition to distinctive R&D and market competition economic characteristics, biopharmaceuticals are also distinguished from other industries by a large gap between the statutory patent term (20 years from the effective patent filing date) and the effective patent term (years remaining at launch), even after any patent term restoration and additional regulatory exclusivity (e.g., for pediatric studies). The average time between brand launch and first generic sale for drugs experiencing initial generic entry in 2011–12 was 12.6 years for drugs with sales greater than $100 million (in 2008 dollars) in the year prior to generic entry, and 12.9 years overall [5]. In contrast, assuming < 3 years for the US Patent and Trademark Office to examine and approve a patent application (overall average of 29 months for FY2013), the remaining duration (assuming 20 years from the effective patent filing date) would be > 17 years in other industries [7].

Medical innovation is crucial to prevent pandemics and mitigate economic harms during shut downs

Mulligan 21 [Casey B. Mulligan– American economist and author. He is a Professor in Economics at the University of Chicago. “Economic activity and the value of medical innovation during a pandemic” Cambridge University Press. 9 June 2021. Link: https://www.cambridge.org/core/journals/journal-of-benefit-cost-analysis/article/economic-activity-and-the-value-of-medical-innovation-during-a-pandemic/864F8042F794D4417E64C643999C9280] JV

Medical innovation can reduce the duration and severity of pandemics. In doing so, innovation reduces the duration and severity of the direct health costs as well as the costs of economic shutdowns intended to mitigate the health costs. As long as it remains a major barrier to medical innovation, regulation will unnecessarily add to the economic and health costs of the current pandemic (Peltzman, 1973; Philipson & Sun, 2008). Innovation is not finished when scientists discover a new medicine, device, or technique and demonstrate its safety. Pandemic medicines and equipment need to be manufactured and distributed on a massive scale. Personnel need to be trained to administer new treatments. These processes can be slowed by regulatory barriers ranging from federal inspections of facilities manufacturing drugs and devices to state occupational licensure. Although not new, disease testing and contact tracing are essential techniques that are scalable in principle, but early in the pandemic were unavailable in the USA in more than small quantities. Regulatory barriers slow both the manufacturing of these devices and techniques as well as the development of more scalable methods for distributing them.

Pandemics are a non-linear, existential risk---encompasses AND outweighs other threats. Empirically proven by historic epidemics such as the Black Death and Spanish flu

Pamlin and Armstrong 15, Dennis Pamlin, Executive Project Manager Global Risks, Global Challenges Foundation, and Stuart Armstrong, James Martin Research Fellow, Future of Humanity Institute, Oxford Martin School, University of Oxford, February 2015, “Global Challenges: 12 Risks that threaten human civilization: The case for a new risk category,” Global Challenges Foundation, p.30-93, https://api.globalchallenges.org/static/wp-content/uploads/12-Risks-with-infinite-impact.pdf //Re DE EK

4 Global A pandemic (from Greek πᾶν, pan, “all”, and δῆμος demos, “people”) is an epidemic of infectious disease that has spread through human populations across a large region; for instance several continents, or even worldwide. Here only worldwide events are included. A widespread endemic disease that is stable in terms of how many people become sick from it is not a pandemic. 260 84 Global Challenges – Twelve risks that threaten human civilisation – The case for a new category of risks 3.1 Current risks 3.1.4.1 Expected impact disaggregation 3.1.4.2 Probability Influenza subtypes266 Infectious diseases have been one of the greatest causes of mortality in history. Unlike many other global challenges pandemics have happened recently, as we can see where reasonably good data exist. Plotting historic epidemic fatalities on a log scale reveals that these tend to follow a power law with a small exponent: many plagues have been found to follow a power law with exponent 0.26.261 These kinds of power laws are heavy-tailed262 to a significant degree.263 In consequence most of the fatalities are accounted for by the top few events.264 If this law holds for future pandemics as well,265 then the majority of people who will die from epidemics will likely die from the single largest pandemic. Most epidemic fatalities follow a power law, with some extreme events – such as the Black Death and Spanish Flu – being even more deadly.267 There are other grounds for suspecting that such a highimpact epidemic will have a greater probability than usually assumed. All the features of an extremely devastating disease already exist in nature: essentially incurable (Ebola268), nearly always fatal (rabies269), extremely infectious (common cold270), and long incubation periods (HIV271). If a pathogen were to emerge that somehow combined these features (and influenza has demonstrated antigenic shift, the ability to combine features from different viruses272), its death toll would be extreme. Many relevant features of the world have changed considerably, making past comparisons problematic. The modern world has better sanitation and medical research, as well as national and supra-national institutions dedicated to combating diseases. Private insurers are also interested in modelling pandemic risks.273 Set against this is the fact that modern transport and dense human population allow infections to spread much more rapidly, and there is the potential for urban slums to serve as breeding grounds for disease.275 Unlike events such as nuclear wars, pandemics would not damage the world’s infrastructure, and initial survivors would likely be resistant to the infection. And there would probably be survivors, if only in isolated locations. Hence the risk of a civilisation collapse would come from the ripple effect of the fatalities and the policy responses. These would include political and agricultural disruption as well as economic dislocation and damage to the world’s trade network (including the food trade). Extinction risk is only possible if the aftermath of the epidemic fragments and diminishes human society to the extent that recovery becomes impossible277 before humanity succumbs to other risks (such as climate change or further pandemics). Five important factors in estimating the probabilities and impacts of the challenge: 1. What the true probability distribution for pandemics is, especially at the tail. 2. The capacity of modern international health systems to deal with an extreme pandemic. 3. How fast medical research can proceed in an emergency. 4. How mobility of goods and people, as well as population density, will affect pandemic transmission. 5. Whether humans can develop novel and effective anti-pandemic solutions.

for the mandatory licensing of patents covering certain devices for reducing air pollution. Importantly, however, the patent owner is accorded due process and the statute lays out a detailed process regulating the manner in which any such license can be issued, including findings of necessity and that no reasonable alternative method to accomplish the legislated goal exists. Also of critical importance is that the statute requires compensation to the patent holder. Similarly, the Atomic Energy Act contemplates mandatory licensing of patents covering inventions of primary importance in producing or utilizing atomic energy. This statute, too, requires due process, findings of importance to the statutory goals and compensation to the rights holder. A TRIPS IP waiver would operate outside of these types of frameworks. There would be no due process, no particularized findings, no compensationand no recourse. Indeed, the fact that the World Trade Organization (WTO) already has a process under the TRIPS agreement to address public health crises, including the compulsory licensing provisions, with necessary guardrails and compensation, makes quite clear that the waiver would operate as a free for all. Forced Tech Transfer Could Be on The Table When being questioned about the scope of a potential TRIPS IP waiver, Ambassador Tai invoked the proverb “Give a man a fish and you feed him for a day. Teach a man to fish and you feed him for a lifetime.” While this answer suggests primarily that, in times of famine, the Administration would rather give away other people’s fishing rods than share its own plentiful supply of fish (here: actual COVID-19 vaccine stocks), it is apparent that in Ambassador Tai’s view waiving patent rights alone would not help lower- and middle-income countries produce their own vaccines. Rather, they would need to be taught how to make the vaccines and given the biotech industry’s manufacturing know-how, sensitive cell lines, and proprietary cell culture media in order to do so. In other words, Ambassador Tai acknowledged that the scope of the current TRIPS IP waiver discussions includes the concept of forced tech transfer. In the context of climate change, the idea would be that companies who develop successful methods for producing new seed technologies and sustainable biomass**,** reducing greenhouse gases in manufacturing and transportation, capturing and sequestering carbon in soil and products, and more, would be required to turn over their proprietaryknow-how to global competitors. While it is unclear how this concept would work in practice and under the constitutions of certain countries, the suggestion alone could be devastating to voluntary internationalcollaborations. Even if one could assume that the United States could not implement forced tech transfer on its own soil, what about the governments of our international development partners? It is not hard to understand that a U.S.-based company developing climate change technologies would be unenthusiastic about partnering with a company abroad knowing that the foreign country’s government is on track – with the assent of the U.S. government – to change its laws and seize proprietary materials and know-how that had been voluntarily transferred to the local company. Necessary Investment Could Diminish Developing climate change solutions is not an easy endeavor and bad policy positions threaten the likelihood that they will materialize. These products have long lead times from research and development to market introduction, owing not only to a high rate of failure but also rigorous regulatory oversight. Significant investment is required to sustain and drive these challenging and long-enduring endeavors. For example, synthetic biology companies critical to this area of innovation [raised over $1 billion in investment in the second quarter of 2019 alone](https://www.bio.org/sites/default/files/2021-04/Climate%20Report_FINAL.pdf). If investors cannot be confident that IP will be in place to protect important climate change technologies after their long road from bench to market, it is unlikely they will continue to investat the current and required levels**.**

#### Climate Patents are critical to solving Warming – only way to stimulate Renewable Energy Technology Investment.

Aberdeen 20 Arielle Aberdeen October 2020 "Patents to climate rescue: how intellectual property rights are fundamental to the development of renewable energy" <https://www.4ipcouncil.com/application/files/4516/0399/1622/Intellectual_Property_and_Renewable_Energy.pdf> (Caribbean Attorney-at-Law with extensive experience in legal research and writing.)//Elmer

**Climate change is** the **most pressing** global **challenge** and with the international commitment to reduce greenhouse gas emissions under the Paris Agreement,1 there **needs to be a global energy revolution** and transition.2 This is where **innovative technology can help** meet the challenge of reducing our dependency on finite natural capital resources. The development and deployment of innovative technology play a pivotal role in enabling us to replace fossil fuel use with more sustainable energy solutions. **Patents** have **facilitated** the **development of such innovative technologies** thus far **and** will **continue to be the catalyst for this transition**. Patents are among a group of intellectual property rights (‘IPRs’). 3 These are private and exclusive rights given for the protection of different types of intellectual creations. IPRs are the cornerstone of developed and knowledge-based economies, as they encourage innovation, drive the investment into new areas and allow for the successful commercialisation of intellectual creations. IPRs are the cornerstone of developed and knowledge-based economies. Empirical evidence has shown that a **strong IPRs** system **influences** both the **development and diffusion of technology**. Alternatively, **weak IPRs** protection has been shown to **reduce** **innovation**, **reduce investment** and prevent firms from entering certain markets.4 Once patent protection has been sought and granted, it gives a time-limited and exclusive rights to the creator of an invention. This allows the inventor or patentor the ability to restrict others from using, selling, or making the new invented product or process. Thereby allowing a timelimited monopoly on the exploitation of the invention in the geographical area where it is protected. During the patent application procedure, the patentor must make sufficient public disclosure of the invention. This will allow others to see, understand and improve upon it, thereby spurring continuous innovation. Therefore, the patent system through providing this economic incentive is a successful tool which has encouraged the development and the dissemination of technology. Patents like all IPRs are key instruments in the global innovation ecosystem.5 When developing innovative technology, patents play a role throughout the “technological life cycle”,6 as shown in Figure 1. This lifecycle involves the invention, research and development (‘R&D’), market development and commercial diffusion. Patents are most effective when sought at the R&D stage. Once a patent has been granted, it becomes an asset which can then be used to7: Gain Market Access: Patents can create market advantages; to develop and secure market position; to gain more freedom to operate within a sector and reduce risks of infringing on other patents; protect inventions from being copied, and removes delaying by innovative firms to release new or improved technology and encourage the expansion of their markets. Negotiation leverage: Patents can build a strong brand or company reputation which can enhance the company’s negotiation power and allow for the creation of equal partnerships. Funding: Patents can generate funding and revenue streams for companies. Having a strong patent portfolio especially in small businesses or start-ups can be used to leverage investor funding; while also be a source of revenue for companies through licensing fees, sales, tax incentives, collateral for loans and access to grants and subsidies. Strategic value: Patents can be used to build “synergistic partnerships”8 through which collaboration on R&D and other partnerships; be used to improve in-house R&D and build and/ or develop more products. As such, obtaining and managing patent as part of a patent and broader IPRs strategy are key tools for business success, especially within highly innovative and technology-driven industries.9 Renewable Energy: The Basics Renewable energy is derived from natural unlimited sources which produce little to no harmful greenhouse gases and other pollutants. 10 Innovative renewable energy technologies (‘RETs’) have created the ability to tap into these sources and convert them to energy which can then be stored, distributed, and consumed at a competitive cost. RETs have developed into a technology ecosystem which consists of alternative energy production, energy conservation and green transportation.11 For energy production, RETs have been developed to generate energy from six main sources. These are: Wind energy: Technology, via off-shore and/or on-shore wind turbines, harnesses the energy produced by the wind. Solar energy: Technology either through concentrated solar power (‘CSP’)and solar photovoltaic (‘PV’) harnesses the energy produced by the sun. Hydropower: Technology either through large-scale or small-scale hydropower plants, captures energy from flowing water. Bioenergy: Technology is used to convert organic material into energy either through burning to produce heat or power or through converting it to a liquid biofuel. Geothermal: Technology is used to capture the energy from the heat produced in the earth’s core. Ocean/Tidal energy: Technology is used to capture the energy produced from waves, tides, salinity gradient energy and ocean thermal energy conversion. Out of these six sources, the wind, solar and hydropower energy sectors are the biggest, the most developed and the most widely used. While geothermal and ocean energy sources are used in a more limited capacity. In particular, the RETs in ocean energy is still at its infancy and thus presents an opportunity for future innovation and commercialisation. Renewable energy is the fastest-growing energy source, with the electricity sector showing the fastest energy transition. 12 In 2016, renewable energy accounted for 12% of final global energy consumption and in 2018, a milestone was reached with renewables being used to generate 26% of global electricity. The source of this energy has been driven by renewable hydropower, as shown in Figure 2, with wind and solar energy trailing behind in energy production. However, the International Energy Agency (‘IRENA’) forecasts that Solar PV will lead RETs to increase capacity in the upcoming years. 13 This rise in renewable energy is due to the increased investment into the sector and the development, diffusion and deployment of innovative RETs. For the period between 2010 and 2019, there were 2.6 trillion US dollars invested in renewable energy. 14 The majority of which being focused on solar energy. 15 This investment has surpassed the investment made into the traditional fossil fuel energy 16 and has been heavily driven by the private sector. 17 The International Energy Agency recent report showed that its members increased the public budgets for energy technology R&D, with the biggest increase in the low-carbon sectors.18 The geographic sources of this investment shown in Figure 3, reveals that the European Union, the United States and Japan are part of the largest investors. This reflects the historic involvement these countries have had in the renewable energy arena and the development of RETs. However, there is now the emergence of China, India and Brazil as large investors in this field. This trend in investment has also coincided with the increase in patenting technology in renewable energy compared to fossil fuels.19 Reports from the World Intellectual Property Office (WIPO), have shown that there has been a **steady increase in patent filing rates in RETs since the mid-1990s**.20 This increase has occurred in the four major renewable sectors, 21 where RETs patents applications were growing steadily from 2005 until reaching a peak in 2013.22 Post-2013, there has been a slight decline in patent filings, which can indicate a maturing of sectors and deployment of technologies.23 Each renewable energy sector is at a different stage of maturity and thus there is a variation of patent ownership. The wind sector is the most mature and consequently has the highest intellectual property ownership and patent grants compared to that of the biofuel sector. 24 IRENA also provides a comprehensive and interactive database for RETs patents. As seen in Figure 4 below, they have collected patent data from the major patent filing jurisdiction25 which shows the breakdown of the patents per type. This information reveals that there is a dominance of patent filings focused on solar technology. This data corresponds to the focus of the investment in renewable energy into solar energy. Upon closer look at the data, the geographic source of these patents shows that RETs patents have been concentrated in a few developed OECD countries and China. This also corresponds to the source of investment shown in Figure 3 and reflects the historical concentration of RETs innovation within these countries. 26 The latest WIPO report for 2019, which looks at the data for PCT patent applications, shows that 76 % of all PCT patent application came from the United States, Germany, Japan, the Republic of Korea and China.27 China is the newest entry into the top ten list and has made one of the largest jumps to become one of the biggest RETs patent filers at the PCT. This geographic data is also mirrored by IRENA’s statistics, as shown in Figure 5 below. This data also reflects China’s emerging renewable dominance. China is heavily **investing in solar energy** **technology** and has filed numerous patents in this area and the underlying technologies.28 The successful flow of investment in this sector can only **occur in** the **presence of a strong IPRs system** and protection. Government policies and initiatives to improve the **patent system** can be used to promote the development of RETs and drive private capital and investment into this area.29 This direct **effect on RETs** through policies was **shown in** the United States with the ‘**Green Tech Pilot Program’**.30 This was a special accelerated patent application procedure developed by the United States Patent and Trademark Office for inventions falling under the green technology category. This program ran from 2009-2011 and led to a boost in RETs patent applications, with the office issuing 1062 RETs patents from the programme. Other jurisdictions, such as the European Union and China have used policy and incentives to promote the development of RETs and the advancement of their renewable energy sector. In particular, the European Union and China began the renewable energy path at different starting points but are now both dominant players in this area.

#### Warming causes Extinction

Kareiva 18, Peter, and Valerie Carranza. "Existential risk due to ecosystem collapse: Nature strikes back." Futures 102 (2018): 39-50. (Ph.D. in ecology and applied mathematics from Cornell University, director of the Institute of the Environment and Sustainability at UCLA, Pritzker Distinguished Professor in Environment & Sustainability at UCLA)//Re-cut by Elmer

In summary, six of the nine proposed planetary boundaries (phosphorous, nitrogen, biodiversity, land use, atmospheric aerosol loading, and chemical pollution) are unlikely to be associated with existential risks. They all correspond to a degraded environment, but in our assessment do not represent existential risks. However, the three remaining boundaries (**climate change**, global **freshwater** cycle, **and** ocean **acidification**) do **pose existential risks**. This is **because of** intrinsic **positive feedback loops**, substantial lag times between system change and experiencing the consequences of that change, and the fact these different boundaries interact with one another in ways that yield surprises. In addition, climate, freshwater, and ocean acidification are all **directly connected to** the provision of **food and water**, and **shortages** of food and water can **create conflict** and social unrest. Climate change has a long history of disrupting civilizations and sometimes precipitating the collapse of cultures or mass emigrations (McMichael, 2017). For example, the 12th century drought in the North American Southwest is held responsible for the collapse of the Anasazi pueblo culture. More recently, the infamous potato famine of 1846–1849 and the large migration of Irish to the U.S. can be traced to a combination of factors, one of which was climate. Specifically, 1846 was an unusually warm and moist year in Ireland, providing the climatic conditions favorable to the fungus that caused the potato blight. As is so often the case, poor government had a role as well—as the British government forbade the import of grains from outside Britain (imports that could have helped to redress the ravaged potato yields). Climate change intersects with freshwater resources because it is expected to exacerbate drought and water scarcity, as well as flooding. Climate change can even impair water quality because it is associated with heavy rains that overwhelm sewage treatment facilities, or because it results in higher concentrations of pollutants in groundwater as a result of enhanced evaporation and reduced groundwater recharge. **Ample clean water** is not a luxury—it **is essential for human survival**. Consequently, cities, regions and nations that lack clean freshwater are vulnerable to social disruption and disease. Finally, ocean acidification is linked to climate change because it is driven by CO2 emissions just as global warming is. With close to 20% of the world’s protein coming from oceans (FAO, 2016), the potential for severe impacts due to acidification is obvious. Less obvious, but perhaps more insidious, is the interaction between climate change and the loss of oyster and coral reefs due to acidification. Acidification is known to interfere with oyster reef building and coral reefs. Climate change also increases storm frequency and severity. Coral reefs and oyster reefs provide protection from storm surge because they reduce wave energy (Spalding et al., 2014). If these reefs are lost due to acidification at the same time as storms become more severe and sea level rises, coastal communities will be exposed to unprecedented storm surge—and may be ravaged by recurrent storms. A key feature of the risk associated with climate change is that mean annual temperature and mean annual rainfall are not the variables of interest. Rather it is extreme episodic events that place nations and entire regions of the world at risk. These extreme events are by definition “rare” (once every hundred years), and changes in their likelihood are challenging to detect because of their rarity, but are exactly the manifestations of climate change that we must get better at anticipating (Diffenbaugh et al., 2017). Society will have a hard time responding to shorter intervals between rare extreme events because in the lifespan of an individual human, a person might experience as few as two or three extreme events. How likely is it that you would notice a change in the interval between events that are separated by decades, especially given that the interval is not regular but varies stochastically? A concrete example of this dilemma can be found in the past and expected future changes in storm-related flooding of New York City. The highly disruptive flooding of New York City associated with Hurricane Sandy represented a flood height that occurred once every 500 years in the 18th century, and that occurs now once every 25 years, but is expected to occur once every 5 years by 2050 (Garner et al., 2017). This change in frequency of extreme floods has profound implications for the measures New York City should take to protect its infrastructure and its population, yet because of the stochastic nature of such events, this shift in flood frequency is an elevated risk that will go unnoticed by most people. 4. The combination of positive feedback loops and societal inertia is fertile ground for global environmental catastrophes **Humans** are remarkably ingenious, and **have adapted** to crises **throughout** their **history**. Our doom has been repeatedly predicted, only to be averted by innovation (Ridley, 2011). **However**, the many **stories** **of** human ingenuity **successfully** **addressing** **existential risks** such as global famine or extreme air pollution **represent** environmental c**hallenges that are** largely **linear**, have immediate consequences, **and operate without positive feedbacks**. For example, the fact that food is in short supply does not increase the rate at which humans consume food—thereby increasing the shortage. Similarly, massive air pollution episodes such as the London fog of 1952 that killed 12,000 people did not make future air pollution events more likely. In fact it was just the opposite—the London fog sent such a clear message that Britain quickly enacted pollution control measures (Stradling, 2016). Food shortages, air pollution, water pollution, etc. send immediate signals to society of harm, which then trigger a negative feedback of society seeking to reduce the harm. In contrast, today’s great environmental crisis of climate change may cause some harm but there are generally long time delays between rising CO2 concentrations and damage to humans. The consequence of these delays are an absence of urgency; thus although 70% of Americans believe global warming is happening, only 40% think it will harm them (http://climatecommunication.yale.edu/visualizations-data/ycom-us-2016/). Secondly, unlike past environmental challenges, **the Earth’s climate system is rife with positive feedback loops**. In particular, as CO2 increases and the climate warms, that **very warming can cause more CO2 release** which further increases global warming, and then more CO2, and so on. Table 2 summarizes the best documented positive feedback loops for the Earth’s climate system. These feedbacks can be neatly categorized into carbon cycle, biogeochemical, biogeophysical, cloud, ice-albedo, and water vapor feedbacks. As important as it is to understand these feedbacks individually, it is even more essential to study the interactive nature of these feedbacks. Modeling studies show that when interactions among feedback loops are included, uncertainty increases dramatically and there is a heightened potential for perturbations to be magnified (e.g., Cox, Betts, Jones, Spall, & Totterdell, 2000; Hajima, Tachiiri, Ito, & Kawamiya, 2014; Knutti & Rugenstein, 2015; Rosenfeld, Sherwood, Wood, & Donner, 2014). This produces a wide range of future scenarios. Positive feedbacks in the carbon cycle involves the enhancement of future carbon contributions to the atmosphere due to some initial increase in atmospheric CO2. This happens because as CO2 accumulates, it reduces the efficiency in which oceans and terrestrial ecosystems sequester carbon, which in return feeds back to exacerbate climate change (Friedlingstein et al., 2001). Warming can also increase the rate at which organic matter decays and carbon is released into the atmosphere, thereby causing more warming (Melillo et al., 2017). Increases in food shortages and lack of water is also of major concern when biogeophysical feedback mechanisms perpetuate drought conditions. The underlying mechanism here is that losses in vegetation increases the surface albedo, which suppresses rainfall, and thus enhances future vegetation loss and more suppression of rainfall—thereby initiating or prolonging a drought (Chamey, Stone, & Quirk, 1975). To top it off, overgrazing depletes the soil, leading to augmented vegetation loss (Anderies, Janssen, & Walker, 2002). Climate change often also increases the risk of forest fires, as a result of higher temperatures and persistent drought conditions. The expectation is that **forest fires will become more frequent** and severe with climate warming and drought (Scholze, Knorr, Arnell, & Prentice, 2006), a trend for which we have already seen evidence (Allen et al., 2010). Tragically, the increased severity and risk of Southern California wildfires recently predicted by climate scientists (Jin et al., 2015), was realized in December 2017, with the largest fire in the history of California (the “Thomas fire” that burned 282,000 acres, https://www.vox.com/2017/12/27/16822180/thomas-fire-california-largest-wildfire). This **catastrophic fire** embodies the sorts of positive feedbacks and interacting factors that **could catch humanity off-guard and produce a** true **apocalyptic event.** Record-breaking rains produced an extraordinary flush of new vegetation, that then dried out as record heat waves and dry conditions took hold, coupled with stronger than normal winds, and ignition. Of course the record-fire released CO2 into the atmosphere, thereby contributing to future warming. Out of all types of feedbacks, water vapor and the ice-albedo feedbacks are the most clearly understood mechanisms. Losses in reflective snow and ice cover drive up surface temperatures, leading to even more melting of snow and ice cover—this is known as the ice-albedo feedback (Curry, Schramm, & Ebert, 1995). As snow and ice continue to melt at a more rapid pace, millions of people may be displaced by flooding risks as a consequence of sea level rise near coastal communities (Biermann & Boas, 2010; Myers, 2002; Nicholls et al., 2011). The water vapor feedback operates when warmer atmospheric conditions strengthen the saturation vapor pressure, which creates a warming effect given water vapor’s strong greenhouse gas properties (Manabe & Wetherald, 1967). Global warming tends to increase cloud formation because warmer temperatures lead to more evaporation of water into the atmosphere, and warmer temperature also allows the atmosphere to hold more water. The key question is whether this increase in clouds associated with global warming will result in a positive feedback loop (more warming) or a negative feedback loop (less warming). For decades, scientists have sought to answer this question and understand the net role clouds play in future climate projections (Schneider et al., 2017). Clouds are complex because they both have a cooling (reflecting incoming solar radiation) and warming (absorbing incoming solar radiation) effect (Lashof, DeAngelo, Saleska, & Harte, 1997). The type of cloud, altitude, and optical properties combine to determine how these countervailing effects balance out. Although still under debate, it appears that in most circumstances the cloud feedback is likely positive (Boucher et al., 2013). For example, models and observations show that increasing greenhouse gas concentrations reduces the low-level cloud fraction in the Northeast Pacific at decadal time scales. This then has a positive feedback effect and enhances climate warming since less solar radiation is reflected by the atmosphere (Clement, Burgman, & Norris, 2009). The key lesson from the long list of potentially positive feedbacks and their interactions is that **runaway climate change,** and runaway perturbations have to be taken as a serious possibility. Table 2 is just a snapshot of the type of feedbacks that have been identified (see Supplementary material for a more thorough explanation of positive feedback loops). However, this list is not exhaustive and the possibility of undiscovered positive feedbacks **portends** even greater **existential risks**. The many environmental crises humankind has previously averted (famine, ozone depletion, London fog, water pollution, etc.) were averted because of political will based on solid scientific understanding. We cannot count on complete scientific understanding when it comes to positive feedback loops and climate change.

## On Case

#### Lack of key supplies

Tepper 21 James Tepper, 4/10 [James Tepper, (James M. Tepper is an American neuroscientist currently a Board of Governors Professor of Molecular and Behavioral Neuroscience and Distinguished Professor at Rutgers University and an Elected Fellow of the American Association for the Advancement of Science.)]. "Global Covid vaccine rollout threatened by shortage of vital components." Guardian, 4-1-2021, Accessed 8-8-2021. https://www.theguardian.com/world/2021/apr/10/global-covid-vaccine-rollout-threatened-by-shortage-of-vital-components // duongie

Vaccine-makers around the world face shortages of vital components including large plastic growbags, according to the head of the firm that is manufacturing a quarter of the UK’s jab supply. Stan Erck, the chief executive of Novavax – which makes the second vaccine to be grown and bottled entirely in Britain – told the Observer that the shortage of 2,000-litre bags in which the vaccine cells were grown was a significant hurdle for global supply. His warning came as bag manufacturers revealed that some pharmaceutical firms were waiting up to 12 months for the sterile single-use disposable plastic containers, which are used to make medicines of all kinds, including the Pfizer, Moderna and Novavax Covid-19 vaccines. But Erck and his British partners said they were confident they had enough suppliers to avoid disruption to the supply of Novavax. The vaccine is waiting for approval from the Medicines and Healthcare products Regulatory Agency (MHRA) but the first of 60 million doses ordered by the government are already in production in Teesside. The Fujifilm Diosynth Biotechnologies factory began growing the first cells for the Novavax vaccine in Billingham, County Durham this month and in a few weeks they will fill the bioreactor bag, ready to be transported to GlaxoSmithKline’s plant at Barnard Castle to be put into vials for distribution. “The first hurdle is showing it works and we don’t have that hurdle any more,” Erck said. But he added there were others still to overcome. “There’s the media that the cells have to grow in,” Erck said. “You grow them in these 2,000-litre bags, which are in short supply. Then you pour it out and you have to filter it, and the filters are in short supply. The little things count.” Novavax almost ran out of bags at one of its 20 factories earlier this year, but there had been no delays for the UK operation, according to Martin Meeson, global chief executive of Fujifilm Diosynth. “We started working on our part of the supply chain in summer last year,” he said. “We had to accelerate some of the investment here, but the commitment we made last summer to start manufacturing in February has been fulfilled.” Production of coronavirus vaccines is being ramped up. Production of coronavirus vaccines is being ramped up. Photograph: Christophe Archambault/AP Both Meeson and Erck said the UK’s vaccine taskforce had been helpful in sorting out supply issues so far, but other countries and other medical supplies might be affected. ABEC makes bioreactor bags at two plants in the US and two in Fermoy and Kells in Ireland, and delivered six 4,000-litre bags to the Serum Institute in India last year for its Covid vaccines. Brady Cole, vice-president of equipment solutions at ABEC, said: “We are hearing from our customer base of lead times that are pushing out to nine, 10, even 12 months to get bioreactor bags. We typically run out at 16 weeks to get a custom bioreactor bag out to a customer.” He said ABEC was still managing to fulfil orders at roughly that rate. “The bag manufacturing capacity can’t meet demand right now,” he added. “And on the component side, the tubes and the instruments and so forth that also go into the bag assembly – those lead times are also starting to get stretched as well. But the biggest problem we see is it really is just the ability to get bags in a reasonable amount of time.” ABEC expanded its factories last year and has now started making 6,000-litre bags, which are roughly the size of a minibus. Other firms including MilliporeSigma, part of German company Merck, have also been expanding their manufacturing facilities. American firm Thermo Fisher Scientific expects it will finish doubling its capacity this year. The US government has also blocked exports of bags, filters and other components so it can supply more Pfizer vaccines for Americans. Adar Poonawalla, the chief executive of the Serum Institute of India, said the restrictions were likely to cause serious bottlenecks. Novavax is hoping to avoid delays and “vaccine nationalism” by operating on four continents, with 20 facilities in nine countries. “One year ago, we had exactly zero manufacturing capacity,” Erck said. “We’re self-sufficient. The two main things we need to do are done in the UK. And in the EU we have plants in Spain and the Czech Republic and fill-and-finish in Germany and the Netherlands.” There was no need for vaccines to cross borders to fulfil contracts, he said. The Oxford/AstraZeneca vaccine was hit by a delay to a delivery of 5 million doses from India and a problem with a batch made in Britain, and the company has been dragged into a lengthy row between the UK and the EU over vaccine exports.

effectiveness stood at 90 percent.

#### 2] Skill Disparities and Trade Secrets – Moderna proves IP isn’t the root cause.

Silverman 3-15 Rachel Silverman 3-15-2021 "Waiving vaccine patents won’t help inoculate poorer nations" <https://www.washingtonpost.com/outlook/2021/03/15/vaccine-coronavirus-patents-waive-global-equity/> (Rachel Silverman is a policy fellow at the Center for Global Development)//Duong

Reality is more complicated, however. Because of the technical complexity of manufacturing coronavirus vaccines, waiving intellectual-property rights, by itself, would have **little effect**. It could even backfire, with companies using the move as an excuse to disengage from global access efforts. There are more effective ways to entice — and to pressure — companies to license and share their intellectual property and the associated know-how, without broadly nullifying patents. The Moderna vaccine illustrates the limits of freeing up intellectual property. Moderna announced in October that it would **not enforce IP rights** on its coronavirus vaccine — and yet it has **taken no steps to share information** about the vaccine’s design or manufacture, citing commercial interests in the underlying technology. Five months later, production of the Moderna vaccine remains entirely under the **company’s direct control** within its owned and contracted facilities. Notably, Moderna is also the only manufacturer of a U.S.- or British-approved vaccine not yet participating in Covax, a global-aid-funded effort (including a pledged $4 billion from the United States) to purchase vaccines for use in low- and middle-income countries. It is true, however, that activist pressure — including threats to infringe upon IP rights — can encourage originators to enter into voluntary licensing arrangements. So the global movement to liberate the vaccine patents may be useful, even if some advocates make exaggerated claims about the effects of waivers on their own. We focused on covid. Now our other patients are suffering. One reason patent waivers are unlikely to help much in this case is that vaccines are harder to make than ordinary drugs. Because most drugs are simple chemical compounds, and because the composition of the compounds is easily analyzable, competent chemists can usually reverse-engineer a production process with relative ease. When a drug patent expires, therefore — or is waived — generic companies can readily enter the market and produce competitive products, lowering prices dramatically. Vaccines, in contrast, are complex biological products. Observing their contents is insufficient to allow for imitation. Instead, to produce the vaccine, manufacturers need access to the developer’s “soft” IP — the proprietary recipe, cell lines, manufacturing processes and so forth. While some of this information is confidentially submitted to regulators and might theoretically be released in an extraordinary situation (though not without legal challenge), manufacturers are at an enormous disadvantage without the originator’s cooperation to help them set up their process and kick-start production. Even with the nonconsensual release of the soft IP held by the regulator, the process of trial and error would cause long delays in a best-case scenario. Most likely, the effort would end in expensive failure. Manufacturers also need certain raw ingredients and other materials, like glass vials and filtration equipment; overwhelming demand, paired with disruptive export restrictions, has constricted the global availability of some of these items.

#### 3)There is a fundamental issue in the drug practices and markets in poor countries – patented drugs are not the problem

**Silverman et al 19**[Rachel Silverman is a policy fellow at the Center for Global Development, where she leads policy-oriented research on global health financing and incentive structures. Janeen Madan Keller is a senior policy analyst and assistant director of global health at the Center for Global Development. Amanda Glassman is executive vice president and senior fellow at the Center for Global Development and also serves as chief executive officer of CGD Europe. Kalipso Chalkidou is the Director of Global Health Policy and a Senior Fellow at the Center for Global Development, Center for Global Development, “New Study Finds Some Poor Countries Paying 20 to 30 Times More for Basic Medicines Than Others”, June 17. 2019, <https://www.cgdev.org/article/new-study-finds-some-poor-countries-paying-20-30-times-more-basic-medicines-others>] DD MN

WASHINGTON – **Basic,** **everyday drugs can cost up to 20 to 30 times more in some poor countries** than others, **according to a new study released today by the Center for Global Development. The study examined billions of dollars of health spending on common, life-saving medicines in developing countries, mostly in Africa and Asia.** To date, it is one of the largest-ever studies on global health procurement.

“Developing countries are often paying far more for everyday drugs than they should be. Why do some poor countries pay 20 to 30 times as much as others for common medicines to relieve pain or treat hypertension? In large part, **because of flawed drug buying practices and broken generic medicines markets**,” said Amanda Glassman, one of the authors of the study and the executive vice president at the Center for Global Development.

“A robust market for generic drugs is a core part of an affordable health system. But in way too many countries, generic drug markets are broken and patients are paying the price,” said Kalipso Chalkidou, the director of global health policy at the Center for Global Development and an author of the study. “You need enough competition to keep prices low and quality assurance that consumers trust, or essential medicines are going to be much more expensive than they should be.”

The study had three main findings:

**In developing countries, prices for basic generic medicines can** vary widely and **far exceed wealthy-country prices**. Some purchasers in low- and middle-income countries pay as much as 20 to 30 times more for basic generic medicines like omeprazole, used to treat heartburn, or acetaminophen (also known as paracetamol), a common pain reliever.

**Low- and middle-income countries purchase more expensive branded generic drugs rather than unbranded quality-assured generics**. In the US, most drugs are either on-patent medicines or unbranded generics, but in many developing countries more expensive brand-name generics are widely used, because people are concerned about unsafe or counterfeit drugs. **In the poorest countries, unbranded generics are only 5 percent of the pharma**ceutical **market** by volume—**in comparison to the US where unbranded** quality-assured **generics are 85 percent of the market** by volume.

**There is little competition in the supply of** essential medicines in low- and middle-income countries. The largest seller of products like contraceptives, cancer medicines, and antiparasitics can account for upwards of 85 percent of all sales in some countries.

“We’re talking about access to **common medications for pain or high blood pressure, not the latest cutting-edge cancer drugs**,” Glassman said.

“It’s not as exciting to talk about procurement as new health technologies or biotech breakthroughs,” she continued. “But drug purchasing is incredibly important, and if it’s done badly you end up with the poorest countries in the world paying some of the highest drug prices.”